TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31241194

Group type: EXPERIMENTAL
Intervention: NO‐ASPIRATE
Number of subjects: 513

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 513
Study: 27214600

Group type: EXPERIMENTAL
Intervention: Low demands
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High demands
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low decision latitude
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High decision latitude
Number of subjects: 80
Study: 25271207

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23485096

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 81
Study: 21685437

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5216

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5216
Study: 19436670

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg once daily, increased to 16 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Amlodipine besylate (AML) 5 mg once daily, increased to 10 mg if BP not normalized, with possible addition of hydrochlorothiazide 12.5 mg
Number of subjects: 209
Study: 16393744

Group type: COMPARATOR
Intervention: Slow-release oral morphine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Opioid clients at admission
Number of subjects: 240
Study: 15196586

Group type: EXPERIMENTAL
Intervention: Metformin IR tablet (500 mg)
Number of subjects: 12
Study: 11417922

Group type: EXPERIMENTAL
Intervention: Right unilateral ECT
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bitemporal treatment (after right unilateral treatment failure)
Number of subjects: 17
Study: 9165286

Group type: EXPERIMENTAL
Intervention: Scheduled hand washing (minimum of four times a day)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (usual hand washing practices)
Number of subjects: 305
Study: 8544367

Group type: EXPERIMENTAL
Intervention: Expression-dependent trait group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Expression-independent trait group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 62
Study: 2320205

Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for newly diagnosed malignant astrocytoma (Group I)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for recurrent malignant astrocytoma (Group II)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy for recurrent solitary cerebral metastasis (Group III)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy overall
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Second operation for clinical and radiological deterioration
Number of subjects: 46
Study: 444956

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg thrice daily for seven days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (for three to seven days)
Number of subjects: 7
Study: 31029148

Group type: EXPERIMENTAL
Intervention: Novel methods for monitoring and managing data return rates, including an automated database report and a Microsoft Excel-based tool.
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Contacting centres regarding falling data return rates.
Number of subjects: 669
Study: 27760719

Group type: EXPERIMENTAL
Intervention: Fibrinogen (FB)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: White blood cell count (WBC)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC)
Number of subjects: 275
Study: 26004173

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maxillary Occlusal Splint (MOS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study: 25240012

Group type: EXPERIMENTAL
Intervention: 2% lidocaine intracervical injection 5 min prior to LNG-IUS insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drug (NSAID) (ibuprofen, 400 mg) 1 h prior to LNG-IUS insertion
Number of subjects: 100
Study: 23099972

Group type: EXPERIMENTAL
Intervention: Topical/intracameral anesthesia (group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Peribulbar anesthesia (group 2)
Number of subjects: 46
Study: 20598832

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Twelve‐Step Facilitation Therapy
Number of subjects: 236
Study: 17903693

Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg every day
Number of subjects: 174

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg every day
Number of subjects: 174
Study: 15649162

Group type: EXPERIMENTAL
Intervention: Aprotinin (30.000 KIU.kg(‐1) after induction, 30.000 KIU.kg(‐1) in pump prime, 30.000 KIU.kg(‐1) after weaning from bypass)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg.kg(‐1) after induction, 100 mg.kg(‐1) in pump prime, 100 mg.kg(‐1) after weaning from bypass)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of aprotinin and tranexamic acid (same dosages as above)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 12237596

Group type: COMPARATOR
Intervention: 1-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 3-day intramuscular ceftriaxone regimen (50 mg/kg/day)
Number of subjects: 170
Study: 10025832

Group type: EXPERIMENTAL
Intervention: 32P
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 89Sr
Number of subjects: 31
Study: 8862377

Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 838
Study: 1324238

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Griseofulvin 500 mg/day
Number of subjects: 61
Study: 6831819

Group type: EXPERIMENTAL
Intervention: gallopamil (50 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: propafenone (150 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: verapamil (80 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: quinidine (250 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 30902369

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Methylene blue dye
Number of subjects: 132
Study: 27740721

Group type: EXPERIMENTAL
Intervention: MF-MDI 50 mcg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF-MDI 100 mcg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MF-MDI 200 mcg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25857939

Group type: EXPERIMENTAL
Intervention: Stretching treatment with a prefabricated orthosis and stretching exercises
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strengthening treatment with a prefabricated orthosis, stretching, and strengthening exercises
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (orthosis wear alone)
Number of subjects: 39
Study: 23187047

Group type: EXPERIMENTAL
Intervention: Delorme operation only (GI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Delorme operation with postanal repair and levatorplasty (GII)
Number of subjects: 82
Study: 20419494

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg PO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Granisetron 3 mg IV + Metoclopramide 20 mg IM (no megestrol acetate)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Megestrol acetate regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: No megestrol acetate regimen
Number of subjects: 100
Study: 19384234

Group type: EXPERIMENTAL
Intervention: Silver-integrated central venous catheters
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard central venous catheters
Number of subjects: 230
Study: 17303485

Group type: EXPERIMENTAL
Intervention: Nova T380
Number of subjects: 957

Group type: COMPARATOR
Intervention: Gyne T380 Slimline
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 957
Study: 15179542

Group type: EXPERIMENTAL
Intervention: Mood and Physical Symptoms Scale (MPSS)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ratings of urges to smoke
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ratings of hunger
Number of subjects: 111
Study: 11702960

Group type: EXPERIMENTAL
Intervention: Hyperfractionation
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Conventional radiation (70 Gy in 7 weeks)
Number of subjects: 1000
Study: 1606999

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg and 100 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg and 100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4075074

Group type: EXPERIMENTAL
Intervention: Semantic treatment (4 sessions over one week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Semantic treatment (8 sessions over two weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phonological treatment (4 sessions over one week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phonological treatment (8 sessions over two weeks)
Number of subjects: 12
Study: 29582641

Group type: EXPERIMENTAL
Intervention: Cervical cancer screening
Number of subjects: 320

Group type: COMPARATOR
Intervention: Marital status
Number of subjects: 320

Group type: COMPARATOR
Intervention: Knowledge
Number of subjects: 320

Group type: COMPARATOR
Intervention: Perceived barriers
Number of subjects: 320

Group type: COMPARATOR
Intervention: Having a regular health care provider
Number of subjects: 320
Study: 27286139

Group type: EXPERIMENTAL
Intervention: Agomelatine (15 mg/day for patients ≥30 kg and 25 mg/day for patients ≥45 kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) (20 mg/day for participants <30 kg and 30 mg/day for patients ≥30 kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 54
Study: 24785925

Group type: EXPERIMENTAL
Intervention: Retention (transpalatal arch)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No retention
Number of subjects: 30
Study: 23536452

Group type: EXPERIMENTAL
Intervention: Arctic Ease cryotherapy wrap
Number of subjects: 13

Group type: COMPARATOR
Intervention: Traditional ice pack and compression wrap (control group)
Number of subjects: 13
Study: 20685951

Group type: EXPERIMENTAL
Intervention: Whole-grain foods (3 daily portions)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Whole-grain foods (wheat + oats)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Refined diet (control)
Number of subjects: 206
Study: 19066755

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0
Study: 16860894

Group type: EXPERIMENTAL
Intervention: BAD (bootstrapped amplitude difference) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCD (bootstrapped correlation difference) method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New approach with wavelet features and a statistical classifier
Number of subjects: 0
Study: 12564610

Group type: EXPERIMENTAL
Intervention: 500 microg sibenadet via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo via pressurized metered dose inhaler (pMDI), three times daily for 52 weeks
Number of subjects: 435
Study: 10627444

Group type: EXPERIMENTAL
Intervention: Intensive ALL-type chemotherapy including moderate cumulative doses of anthracyclines (240 mg/m²) and cyclophosphamide (3 g/m²) with prophylactic cranial irradiation (12 Gy)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for patients with less than 70% tumor regression on day 33
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with tumor residues after induction
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with complete tumor regression
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Overall events
Number of subjects: 105
Study: 8972656

Group type: EXPERIMENTAL
Intervention: Helical CT
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 33
Study: 1735396

Group type: EXPERIMENTAL
Intervention: Diclofenac 37.5 mg or 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin 25 mg or 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxycodone 5 mg or 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study: 3544689

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg tid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg bid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3-dose regimen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2-dose regimen
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both 2-dose and 3-dose regimens
Number of subjects: 12
Study: 29718556

Group type: EXPERIMENTAL
Intervention: Football training and dietary advice (F+D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dietary advice (D)
Number of subjects: 50
Study: 27394191

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 200
Study: 24456823

Group type: COMPARATOR
Intervention: Temsirolimus 25mg weekly
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Temsirolimus with megestrol acetate 80 mg bid for three weeks alternating with tamoxifen 20mg bid for three weeks
Number of subjects: 71
Study: 23250594

Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MENS) in addition to standard treatment (n=36)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MENS) in combination with cortexin (n=38)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard therapy using massage and gymnastics (n=31)
Number of subjects: 105
Study: 22216654

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.3% triclosan, 2.0% PVM/MA copolymer, 0.243% sodium fluoride, specially-designed silica)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Negative Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 115
Study: 19268053

Group type: EXPERIMENTAL
Intervention: Allergen avoidance for 1 month (T1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Allergen avoidance for 4 months (T2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Allergen avoidance regimen
Number of subjects: 22
Study: 17044273

Group type: EXPERIMENTAL
Intervention: Coated stents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 60
Study: 12769249

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 894

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 894
Study: 11141203

Group type: EXPERIMENTAL
Intervention: Initial standard rate intervention (80-90 beats/min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Initial high rate intervention (120 beats/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard rate)
Number of subjects: 20
Study: 9180672

Group type: EXPERIMENTAL
Intervention: DHEAS (7.5 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 1610024

Group type: EXPERIMENTAL
Intervention: Pemirolast 50 mg BID
Number of subjects: 96

Group type: COMPARATOR
Intervention: Pemirolast 25 mg BID
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 3864227

Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, high P/S ratio diet 0.4-1.1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, P/S ratio 0.9) with 60% salt reduction
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low fat diet (less than 25 en% total fat, P/S ratio 0.4 and 0.9)
Number of subjects: 3
Study: 30456961

Group type: EXPERIMENTAL
Intervention: Shiga toxin-producing Escherichia coli (STEC) isolates
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility testing
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Detection of class 1 integrons
Number of subjects: 540
Study: 26739977

Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-elastic abdominal binder
Number of subjects: 57
Study: 24642702

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (MMI)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Cognitive-based-behavioral therapy (CBT)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 278
Study: 22345500

Group type: EXPERIMENTAL
Intervention: Alteplase delivered through a microcatheter embedded within the thrombus at 1 mg per minute, not exceeding 100 mg total
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard alteplase delivery method without optimization
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Optimizing alteplase delivery
Number of subjects: 85
Study: 19895624

Group type: EXPERIMENTAL
Intervention: Comprehensive cognitive behaviourally oriented service (CBOS)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 169
Study: 17986242

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (20 mug type 6, 40 mug type 11, 40 mug type 16, and 20 mug type 18)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 16095844

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Psycho-education (PET)
Number of subjects: 88
Study: 11849196

Group type: EXPERIMENTAL
Intervention: Dofetilide 1.0 mg twice daily for 23 days and once on day 24 (continuous dosing)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Dofetilide 1.0 mg single dose on days 1, 5, 10, 17, and 24 (intermittent dosing)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (matching placebo capsules under the same regimen as group 1)
Number of subjects: 3
Study: 10399790

Group type: EXPERIMENTAL
Intervention: Nodular RA
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Non-nodular RA
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (Osteoarthrosis and Spondyloarthrosis)
Number of subjects: 105
Study: 7741287

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms.kg‐1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms.kg‐1
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 96
Study: 2126672

Group type: EXPERIMENTAL
Intervention: Tenidap (CP-66,248)
Number of subjects: 10
Study: 7234399

Group type: EXPERIMENTAL
Intervention: Cytological examination of cerebrospinal fluid with histiomonocytic counts greater than 10 M. elements/l and granulocytic peaks greater than 2 M. elements/l
Number of subjects: 57
Study: 31837726

Group type: EXPERIMENTAL
Intervention: Varied Practice (n=405)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Repeated Reading (n=422)
Number of subjects: 827
Study: 28379486

Group type: EXPERIMENTAL
Intervention: Kinetic modeling with postdialysis serum creatinine measurement
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Kinetic modeling without postdialysis serum creatinine measurement
Number of subjects: 366

Group type: COMPARATOR
Intervention: Diffusive cross-dialyzer clearances of urea
Number of subjects: 366
Study: 26485128

Group type: EXPERIMENTAL
Intervention: Contact intervention (testimonies, participatory videos, and comics during contact events)
Number of subjects: 4443
Study: 23408577

Group type: COMPARATOR
Intervention: Alendronate (ALN) therapy for 5 years followed by a 5-year treatment-free period (placebo arm of the FLEX trial)
Number of subjects: 406
Study: 21555291

Group type: EXPERIMENTAL
Intervention: Pharmacists providing information regarding medication's name (93.3%)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pharmacists providing dosage schedule (92.8%)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pharmacists advising daily medication intake (92.6%)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pharmacists informing about time to effect (87.8%)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pharmacists providing less information to Spanish-speaking patients (β = ‐0.24)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pharmacists providing less education messages to Spanish-speaking patients (β = ‐0.17)
Number of subjects: 540
Study: 19379703

Group type: EXPERIMENTAL
Intervention: Bis-PAGE protocol for bisulfite conversion
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Capillary-based size analysis and Sanger sequencing
Number of subjects: 200
Study: 17038641

Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs
Number of subjects: 26
Study: 15243743

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: TAPP repair
Number of subjects: 280
Study: 11078635

Group type: EXPERIMENTAL
Intervention: iobitridol (20 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: normal saline solution (20 ml)
Number of subjects: 20
Study: 9093234

Group type: EXPERIMENTAL
Intervention: Suppressive therapy for disseminated or invasive fungal infections; details on dosage and duration not available.
Number of subjects: 0
Study: 8287659

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2892963

Group type: EXPERIMENTAL
Intervention: 0.5% Timolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.6% Metipranolol
Number of subjects: 15

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1% Pindolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3% Pilocarpin
Number of subjects: 15